Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$136.36

3.93 (2.97%)

, SAGE

Sage Therapeutics

$126.62

-10.64 (-7.75%)

08:20
11/06/18
11/06
08:20
11/06/18
08:20

RBC Capital to hold a bus tour

Biotech Bus Tour travels throughout Boston on November 6.

BLUE

Bluebird Bio

$136.36

3.93 (2.97%)

SAGE

Sage Therapeutics

$126.62

-10.64 (-7.75%)

SRPT

Sarepta

$139.53

-6.32 (-4.33%)

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

  • 13

    Dec

  • 19

    Dec

BLUE Bluebird Bio
$136.36

3.93 (2.97%)

11/05/18
JANY
11/05/18
UPGRADE
JANY
Buy
Bluebird Bio upgraded to Buy from Neutral at Janney Montgomery Scott
11/05/18
WEDB
11/05/18
NO CHANGE
Target $166
WEDB
Outperform
Bluebird Bio price target lowered to $166 from $204 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Bluebird Bio to $166 from $204, while reiterating an Outperform rating on the shares. The analyst looks forward to a catalyst-filled ASH for the company that will be highlighted by a first look at next-gen BCMA-CAR-T candidate bb21217 in multiple myeloma and initial results from its Phase 1 study of shRNAmiR-LLV gene therapy for sickle cell disease. Nierengarten also notes that Bluebird has provided an update on its SCD registration strategy following the recent FDA-ASH SCD clinical endpoints workshop. He believes that the update increases the program's probability of success, but also pushes out the program's development timeline at least two years.
11/05/18
JANY
11/05/18
UPGRADE
Target $170
JANY
Buy
Janney Montgomery Scott upgrades Bluebird Bio to Buy ahead of ASH
As previously reported, Janney Montgomery Scott analyst Yun Zhong upgraded Bluebird Bio to Buy from Neutral, stating that he does not believe any company-specific reasons were behind the weakness seen in the stock since the end of August. With the stock having lost over 40% from its March peak, Zhong now sees a much more favorable valuation and he also expects more detailed data to be provided at the ASH conference driving further stock outperformance. Zhong maintains a $170 fair value estimate on Bluebird Bio shares.
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
Overweight
Piper says ASH meeting 'will be major' for Bluebird Bio
Piper Jaffray analyst Tyler Van Buren said it "makes sense" that Bluebird Bio has reached an agreement with the FDA to adjust the HGB-206 primary efficacy endpoint to be based on HbA-T87Q expression and total hemoglobin. However, he is awaiting additional clinical data at ASH or in the future to better gauge the probability of success for the pivotal program. While noting that bb2121 is the furthest anti-BCMA program in development, he also prefers to await "the wealth of data" to be reported from other anti-BCMA programs at ASH to more accurately assess bb2121's market opportunity, Van Buren tells investors. The analyst, who sees ASH being "a major event for Bluebird," keeps an Overweight rating on the shares.
SAGE Sage Therapeutics
$126.62

-10.64 (-7.75%)

10/31/18
BMOC
10/31/18
NO CHANGE
Target $203
BMOC
Outperform
BMO sees approval for Sage after Zulresso briefing docs
The FDA this morning released briefing documents for Friday's panel meeting to discuss Sage Therapeutics' Zulresso to treat postpartum depression. It appears the FDA is satisfied with the drug's efficacy and overall tolerability and recognizes a significant unmet need for postpartum depression, BMO Capital analyst Gary Nachman tells investors in a research note. He believes Zulresso will likely be approved on the December 19 FDA action date. Nachman adds, however, that there are some questions on the recommended dosing, since initially the lower dose appears more effective but the doses start to separate during titration when going out beyond 24 hours. He has an Outperform rating on Sage Therapeutics with a $203 price target. The stock in early trading is up 1% to $122.47.
10/31/18
10/31/18
NO CHANGE
Target $206

Overweight
Sage briefing docs 'clearly supportive of approval,' says Piper Jaffray
In a midday research note partially titled "Nothing Too Spooky in Brex Briefing Docs," Piper Jaffray analyst Danielle Brill says this morning's FDA's briefing documents for Sage Therapeutics' brexanolone were overall supportive of approval for postpartum depression. The agency appears comfortable with brexanolone's efficacy, and focused on recommended dosing as a key topic of discussion, Brill writes in a note to investors. The major safety concern, loss of consciousness during infusion which occurred in 4% of women treated, does not appear to be barring of approval, says the analyst. However, Brill adds that while she views the tone of the docs as "clearly supportive of approval," prohibiting administration "at-home" has "obvious negative implications for commercial potential." She has an Overweight rating on Sage Therapeutics with a $206 price target. The stock in midday trading is up 6%, or $7.77, to $129.00.
11/01/18
ADAM
11/01/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics FDA briefing documents read 'ok,' says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA posted its briefing documents related to Sage Therapeutics' brexanolone ahead of the advisory committee meeting on the product scheduled for November 2. The analyst said they appear "ok" and said the drug could be the first approved for the treatment of post-partum depression. The analyst said with the stock down roughly 10% since the FDA confirmed the date of the AdCom meeting, he is telling investors to buy the shares. Kulkarni reiterated his Buy rating and $220 price target on Sage Therapeutics shares.
10/17/18
STFL
10/17/18
NO CHANGE
Target $239
STFL
Buy
Stifel confident in approval of Sage Therapeutics' brexanolone ahead of AdComm
Ahead of an FDA advisory committee meeting on Nov 2 to review brexanolone, Stifel analyst Paul Matteis said he is confident in FDA approval and expects the debate on the drug to be centered on labeling, REMS and necessary monitoring requirements. While noting that brexanolone comprises a minority of his Sage valuation, Matteis said the most important thing for the stock is that the panel is both positive and doesn't raise any sort of issue that would read negatively onto SAGE-217, which comprises the majority of his Sage valuation. He maintains a Buy rating and $239 price target on Sage Therapeutics shares.
SRPT Sarepta
$139.53

-6.32 (-4.33%)

10/16/18
JMPS
10/16/18
NO CHANGE
Target $270
JMPS
Outperform
JMP likes risk-reward in Sarepta deal for MPS IIIA gene therapy
After Sarepta announced a deal to gain U.S. commercial rights to a potential gene therapy treatment for Mucopolysaccharidosis type IIIA, or MPS IIIA, JMP Securities analyst Liisa A. Bayko said she likes the risk-reward given the relatively limited committed capital and development responsibilities in exchange for full U.S. rights to a late-stage "shot on goal." The analyst, who noted this represents Sarepta's fourth gene therapy deal this year, keeps an Outperform rating and $270 price target on Sarepta shares.
11/06/18
SBSH
11/06/18
INITIATION
Target $25
SBSH
Sell
Solid Biosciences initiated with a Sell at Citi
Citi analyst Joel Beatty started Solid Biosciences (SLDB) with a Sell rating and $25 price target. The analyst believes the gene therapy agents in clinical development for Duchenne muscular dystrophy by Sarepta (SRPT) and Pfizer (PFE) will leave little market share to Solid Bio's SGT-001. The analyst forecasts Sarepta capturing the largest share of the DMD gene therapy market, followed by Pfizer, and then Solid.
11/06/18
SBSH
11/06/18
NO CHANGE
Target $188
SBSH
Buy
Sarepta price target raised to $188 from $174 at Citi
Citi analyst Joel Beatty raised his price target for Sarepta Therapeutics to $188 following an in-depth analysis of the three Duchenne muscular dystrophy gene therapy programs in development. Based on the analysis, the analyst has a higher conviction that Sarepta will have "significant market share." He keeps a Buy rating on the shares.
10/25/18
PIPR
10/25/18
NO CHANGE
Target $168
PIPR
Overweight
Sarepta price target lowered to $168 from $189 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Sarepta Therapeutics to $168 from $189 and keeps an Overweight rating on the name following the company's Q3 results. Exondys51 sales were in-line at $78.5M in Q3 and management reiterated guidance of $295-$305M for this year, Tenthoff tells investors in a research note. He believes Exondys51 sales of $300M this year "are plateauing" and now forecasts $344M of sales in 2019. The analyst, however, says micro-dystrophin GeneRx is advancing and could treat up to 70% of Duchenne muscular dystrophy boys. He thinks this will erode exon-skipping sales upon approval in 2020.

TODAY'S FREE FLY STORIES

08:50
02/19/19
02/19
08:50
02/19/19
08:50
Conference/Events
Cowen Washington research group to hold a meeting »

Cowen's Washington…

ECL

Ecolab

$163.45

1.82 (1.13%)

08:50
02/19/19
02/19
08:50
02/19/19
08:50
Earnings
Ecolab sees FY19 adj. EPS $5.80-$6.00, consensus $5.91 »

The outlook provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 28

    May

CRUS

Cirrus Logic

$40.00

0.85 (2.17%)

08:48
02/19/19
02/19
08:48
02/19/19
08:48
Conference/Events
Cirrus Logic management to meet with Cowen »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

ECL

Ecolab

$163.45

1.82 (1.13%)

08:47
02/19/19
02/19
08:47
02/19/19
08:47
Earnings
Ecolab reports Q4 adj. EPS $1.54, consensus $1.54 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 28

    May

ORTX

Orchard Therapeutics

$15.08

0.58 (4.00%)

08:47
02/19/19
02/19
08:47
02/19/19
08:47
Conference/Events
Orchard Therapeutics management to meet with Cowen »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

GSK

GlaxoSmithKline

$41.24

0.38 (0.93%)

08:46
02/19/19
02/19
08:46
02/19/19
08:46
Conference/Events
GlaxoSmithKline management to meet with Cowen »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 18

    May

GMDA

Gamida Cell

$13.25

0.3 (2.32%)

, EDIT

Editas Medicine

$20.09

0.22 (1.11%)

08:45
02/19/19
02/19
08:45
02/19/19
08:45
Hot Stocks
Gamida Cell, Editas Medicine announce agreement to evaluate use of CRISPR tech »

Gamida Cell (GMDA)…

GMDA

Gamida Cell

$13.25

0.3 (2.32%)

EDIT

Editas Medicine

$20.09

0.22 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

EXPD

Expeditors

$73.56

-0.45 (-0.61%)

08:45
02/19/19
02/19
08:45
02/19/19
08:45
Earnings
Expeditors reports Q4 EPS $1.02, consensus 85c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPO

Midstates Petroleum

$9.25

-0.17 (-1.80%)

, AXDX

Accelerate Diagnostics

$19.82

0.65 (3.39%)

08:45
02/19/19
02/19
08:45
02/19/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

MPO

Midstates Petroleum

$9.25

-0.17 (-1.80%)

AXDX

Accelerate Diagnostics

$19.82

0.65 (3.39%)

WATT

Energous

$8.91

0.11 (1.25%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

NIO

NIO Inc.

$7.41

-0.07 (-0.94%)

EPD

Enterprise Products

$28.21

0.01 (0.04%)

NBEV

New Age Beverages

$6.50

-0.08 (-1.22%)

ITB

iShares U.S. Home Construction ETF

$35.22

0.36 (1.03%)

CWH

Camping World

$15.11

-0.105 (-0.69%)

SAND

Sandstorm Gold

$5.49

0.06 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 22

    Feb

  • 27

    Feb

  • 04

    Mar

WBC

Wabco

$116.78

0.19 (0.16%)

08:44
02/19/19
02/19
08:44
02/19/19
08:44
Recommendations
Wabco analyst commentary  »

Baird would be aggressive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$3.80

0.28 (7.95%)

08:43
02/19/19
02/19
08:43
02/19/19
08:43
Conference/Events
Adverum Biotechnologies management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 27

    Feb

DPZ

Domino's Pizza

$281.63

-5.46 (-1.90%)

08:43
02/19/19
02/19
08:43
02/19/19
08:43
Recommendations
Domino's Pizza analyst commentary  »

Domino's Pizza price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 14

    Mar

08:42
02/19/19
02/19
08:42
02/19/19
08:42
Conference/Events
UBS pharmaceuticals analyst to hold an analyst/industry conference call »

Pharmaceuticals Analyst…

GVA

Granite Construction

$45.48

0.59 (1.31%)

08:42
02/19/19
02/19
08:42
02/19/19
08:42
Hot Stocks
Granite's Water and Mineral Services Group awarded $22.5M in sewer projects »

Granite announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

WWW

Wolverine World Wide

$39.54

0.94 (2.44%)

08:42
02/19/19
02/19
08:42
02/19/19
08:42
Recommendations
Wolverine World Wide analyst commentary  »

Fresh Pick designation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

MCEP

Mid-Con Energy

$0.98

0.06 (6.52%)

08:41
02/19/19
02/19
08:41
02/19/19
08:41
Hot Stocks
Mid-Con Energy sell Texas properties for $60M, buys Oklahoma assets for $27.5M »

Mid-Con Energy, through…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$16.95

(0.00%)

08:41
02/19/19
02/19
08:41
02/19/19
08:41
Recommendations
Kratos Defense analyst commentary  »

Kratos Defense price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEP

PepsiCo

$115.89

3.4 (3.02%)

, KO

Coca-Cola

$45.25

-0.345 (-0.76%)

08:41
02/19/19
02/19
08:41
02/19/19
08:41
Upgrade
PepsiCo, Coca-Cola rating change  »

Macquarie upgrades…

PEP

PepsiCo

$115.89

3.4 (3.02%)

KO

Coca-Cola

$45.25

-0.345 (-0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 03

    Mar

  • 18

    May

HMST

HomeStreet

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Recommendations
HomeStreet analyst commentary  »

HomeStreet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$62.38

0.03 (0.05%)

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Recommendations
Henry Schein analyst commentary  »

Henry Schein price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

GPC

Genuine Parts

$107.49

1.7447 (1.65%)

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Hot Stocks
Breaking Hot Stocks news story on Genuine Parts »

Genuine Parts sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Apr

AEO

American Eagle

$20.07

-0.03 (-0.15%)

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Hot Stocks
American Eagle announces license agreement to expand brands to Europe »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GPC

Genuine Parts

$107.49

1.7447 (1.65%)

08:37
02/19/19
02/19
08:37
02/19/19
08:37
Hot Stocks
Genuine Parts reports Q4 sales for Automotive Group up 11.4% »

Fourth quarter sales for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Apr

CHFS

CHF Solutions

$10.05

0.75 (8.06%)

08:37
02/19/19
02/19
08:37
02/19/19
08:37
Hot Stocks
CHF Solutions enters South American market with Bragenix distribution agreement »

CHF Solutions announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

MRVL

Marvell

$18.82

-0.37 (-1.93%)

08:37
02/19/19
02/19
08:37
02/19/19
08:37
Upgrade
Marvell rating change  »

Marvell upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.